

Quality for Biologics

Part Four: Regulatory Considerations Regarding Product Quality

Regulatory authority expectations, risk management and comparability concerns

Table of Contents

Chapter 12 Current Safety and Efficacy Concerns of the Regulatory Authorities

Frits Lekkerkerker MD, Former CHMP Member and Chairman, Medicines Evaluation Board, Netherlands, Member Advisory Board, NDA Regulatory Science Ltd

1. History
2. New regulatory guidance
3. Expectations of the regulatory authorities
4. Where the industry tends to go wrong
5. Will biologics become harder to regulate?

Chapter 13 Requirements for an Effective CMC Regulatory Compliance Strategy

Steffen Gross, PhD, Laboratory Head and Scientific Assessor (Quality, Pre-clinic Section Monoclonal and Polyclonal Antibodies, Paul-Ehrlich-Institute, Germany

1. Introduction
2. CMC requirements for dossier filing
3. Development of a product - interaction with regulatory authorities

Chapter 14 Regulatory Considerations in Performing Comparability Studies for Biotechnology Products: An Industry Perspective

**Wassim Nashabeh Ph.D., Director, CMC Regulatory Affairs,
Ron Taticek Ph.D., Director, CMC Regulatory Affairs,
Reed J. Harris, BSc, Senior Director, Protein Analytical Chemistry
Genentech, Inc., USA.**

1. Introduction
2. Definitions and scope
3. General principles

About the Contributors